Enarodustat (formerly known as JTZ951;
JTZ-951; trade name in Japan: Enaroy), the hydrochloride salt of Enarodustat, is a potent and orally bioavailable inhibitor of hypoxia inducible factor-proly
hydroxylase (HIF-PH) that has been approved in 2020 for use in Japan for the
treatment of anemia associated with chronic kidney disease (CKD).
纯度:≥98%
CAS:1262131-60-1